• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by AVROBIO Inc.

    6/25/24 4:23:25 PM ET
    $AVRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AVRO alert in real time by email
    SC 13D 1 d780356dsc13d.htm SC 13D SC 13D

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. )

     

     

    TECTONIC THERAPEUTIC, INC.

    (Name of Issuer)

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

    878972108

    (CUSIP Number)

    Lauren Crockett

    Polaris Partners

    One Marina Park Drive, 8th Floor

    Boston, MA 02210

    (781) 290-0770

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    June 20, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    (Continued on following pages)

     


    CUSIP No. 878972108       13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Terrance McGuire

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     0

        8   

     SHARED VOTING POWER

     

     1,157,976 shares of Common Stock (1)

        9   

     SOLE DISPOSITIVE POWER

     

     0

       10   

     SHARED DISPOSITIVE POWER

     

     1,157,976 shares of Common Stock (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,157,976 shares of Common Stock (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     7.9% (2)

    14  

     TYPE OF REPORTING PERSON (see instructions)

     

     IN

     

    (1)

    Consists of (i) 20,262 shares of Common Stock (as defined in Item 1 below) held by PFC I (as defined in Item 2(a) below), (ii) 64,652 shares of Common Stock held by PFC II (as defined in Item 2(a) below) and (iii) 1,073,062 shares of Common Stock held by PP IX (as defined in Item 2(a) below). The aggregate amount beneficially owned does not include 11,760 shares of Common Stock granted to Mr. McGuire in his capacity as a director of the Issuer because such shares are not exercisable as of the date of filing this Statement (as defined in Item 1 below) or within 60 days thereafter. PFCM I (as defined in Item 2(a) below) is the general partner of PFC I. Each of Mr. Flint and Mr. McGuire, a member of the Issuer’s (as defined in Item 1 below) board of directors, are managing members of PFCM I. Each of PFCM I, Mr. Flint and Mr. McGuire may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PFC I. PFCM II (as defined in Item 2(a) below) is the general partner of PFC II. Each of Mr. Flint and Mr. McGuire, a member of the Issuer’s board of directors, are managing members of PFCM II. Each of PFCM II, Mr. Flint and Mr. McGuire may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PFC II. PP GP IX (as defined in Item 2(a) below) is the general partner of PP IX. The PP GP IX Managing Members (as defined in Item 2(c) below) are the managing members of PP GP IX, and Mr. McGuire, a member of the Issuer’s board of directors, is an interest holder in PP GP IX. Each of PP GP IX, the PP GP IX Managing Members and Mr. McGuire may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PP IX.

    (2)

    Based on 14,734,323 shares of Common Stock outstanding upon the Closing (as defined in Item 3 below) of the Business Combination (as defined in Item 3 below), as reported to the Reporting Persons (as defined in Item 2(a) below) by the Issuer.


    CUSIP No. 878972108       13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Polaris Partners IX, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     WC

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     0

        8   

     SHARED VOTING POWER

     

     1,073,062 shares of Common Stock (1)

        9   

     SOLE DISPOSITIVE POWER

     

     0

       10   

     SHARED DISPOSITIVE POWER

     

     1,073,062 shares of Common Stock (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,073,062 shares of Common Stock (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     7.3% (2)

    14  

     TYPE OF REPORTING PERSON (see instructions)

     

     PN

     

    (1)

    All shares are held of record by PP IX. PP GP IX is the general partner of PP IX. The PP GP IX Managing Members are the managing members of PP GP IX, and Mr. McGuire, a member of the Issuer’s board of directors, is an interest holder in PP GP IX. Each of PP GP IX, the PP GP IX Managing Members and Mr. McGuire may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PP IX.

    (2)

    Based on 14,734,323 shares of the Issuer’s Common Stock outstanding as of the Closing, as reported to the Reporting Persons by the Issuer.


    CUSIP No. 878972108       13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Polaris Partners GP IX, L.L.C.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     0

        8   

     SHARED VOTING POWER

     

     1,073,062 shares of Common Stock (1)

        9   

     SOLE DISPOSITIVE POWER

     

     0

       10   

     SHARED DISPOSITIVE POWER

     

     1,073,062 shares of Common Stock (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,073,062 shares of Common Stock (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     7.3% (2)

    14  

     TYPE OF REPORTING PERSON (see instructions)

     

     OO

     

    (1)

    All shares are held of record by PP IX. PP GP IX is the general partner of PP IX. The PP GP IX Managing Members are the managing members of PP GP IX, and Mr. McGuire, a member of the Issuer’s board of directors, is an interest holder in PP GP IX. Each of PP GP IX, the PP GP IX Managing Members and Mr. McGuire may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PP IX.

    (2)

    Based on 14,734,323 shares of the Issuer’s Common Stock outstanding as of the Closing, as reported to the Reporting Persons by the Issuer.


    CUSIP No. 878972108       13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Polaris Founders Capital Fund I, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     WC

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     0

        8   

     SHARED VOTING POWER

     

     20,262 shares of Common Stock (1)

        9   

     SOLE DISPOSITIVE POWER

     

     0

       10   

     SHARED DISPOSITIVE POWER

     

     20,262 shares of Common Stock (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     20,262 shares of Common Stock (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     0.1% (2)

    14  

     TYPE OF REPORTING PERSON (see instructions)

     

     PN

     

    (1)

    All shares are held of record by PFC I. PFCM I is the general partner of PFC I. Each of Mr. Flint and Mr. McGuire, a member of the Issuer’s board of directors, are managing members of PFCM I. Each of PFCM I, Mr. Flint and Mr. McGuire may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PFC I.

    (2)

    Based on 14,734,323 shares of the Issuer’s Common Stock outstanding as of the Closing, as reported to the Reporting Persons by the Issuer.


    CUSIP No. 878972108       13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Polaris Founders Capital Fund Management Co. I, L.L.C.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     0

        8   

     SHARED VOTING POWER

     

     20,262 shares of Common Stock (1)

        9   

     SOLE DISPOSITIVE POWER

     

     0

       10   

     SHARED DISPOSITIVE POWER

     

     20,262 shares of Common Stock (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     20,262 shares of Common Stock (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     0.1% (2)

    14  

     TYPE OF REPORTING PERSON (see instructions)

     

     OO

     

    (1)

    All shares are held of record by PFC I. PFCM I is the general partner of PFC I. Each of Mr. Flint and Mr. McGuire, a member of the Issuer’s board of directors, are managing members of PFCM I. Each of PFCM I, Mr. Flint and Mr. McGuire may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PFC I.

    (2)

    Based on 14,734,323 shares of the Issuer’s Common Stock outstanding as of the Closing, as reported to the Reporting Persons by the Issuer.


    CUSIP No. 878972108       13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Polaris Founders Capital Fund II, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     WC

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     0

        8   

     SHARED VOTING POWER

     

     64,652 shares of Common Stock (1)

        9   

     SOLE DISPOSITIVE POWER

     

     0

       10   

     SHARED DISPOSITIVE POWER

     

     64,652 shares of Common Stock (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     64,652 shares of Common Stock (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     0.4% (2)

    14  

     TYPE OF REPORTING PERSON (see instructions)

     

     PN

     

    (1)

    All shares are held of record by PFC II. PFCM II is the general partner of PFC II. Each of Mr. Flint and Mr. McGuire, a member of the Issuer’s board of directors, are managing members of PFCM II. Each of PFCM II, Mr. Flint and Mr. McGuire may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PFC II.

    (2)

    Based on 14,734,323 shares of the Issuer’s Common Stock outstanding as of the Closing, as reported to the Reporting Persons by the Issuer.


    CUSIP No. 878972108       13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Polaris Founders Capital Fund Management Co. II, L.L.C.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     WC

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     0

        8   

     SHARED VOTING POWER

     

     64,652 shares of Common Stock (1)

        9   

     SOLE DISPOSITIVE POWER

     

     0

       10   

     SHARED DISPOSITIVE POWER

     

     64,652 shares of Common Stock (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     64,652 shares of Common Stock (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     0.4% (2)

    14  

     TYPE OF REPORTING PERSON (see instructions)

     

     OO

     

    (1)

    All shares are held of record by PFC II. PFCM II is the general partner of PFC II. Each of Mr. Flint and Mr. McGuire, a member of the Issuer’s board of directors, are managing members of PFCM II. Each of PFCM II, Mr. Flint and Mr. McGuire may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PFC II.

    (2)

    Based on 14,734,323 shares of the Issuer’s Common Stock outstanding as of the Closing, as reported to the Reporting Persons by the Issuer.


    CUSIP No. 878972108       13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Jonathan Flint

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     0

        8   

     SHARED VOTING POWER

     

     84,914 shares of Common Stock (1)

        9   

     SOLE DISPOSITIVE POWER

     

     0

       10   

     SHARED DISPOSITIVE POWER

     

     84,914 shares of Common Stock (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     84,914 shares of Common Stock (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     0.6% (2)

    14  

     TYPE OF REPORTING PERSON (see instructions)

     

     IN

     

    (1)

    Consists of (i) 28,230 shares of Common Stock held by PFC I and (ii) 90,077 shares of Common Stock held by PFC II. PFCM I is the general partner of PFC I. Each of Mr. Flint and Mr. McGuire, a member of the Issuer’s board of directors, are managing members of PFCM I. Each of PFCM I, Mr. Flint and Mr. McGuire may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PFC I. PFCM II is the general partner of PFC II. Each of Mr. Flint and Mr. McGuire, a member of the Issuer’s board of directors, are managing members of PFCM II. Each of PFCM II, Mr. Flint and Mr. McGuire may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PFC II.

    (2)

    Based on 14,734,323 shares of the Issuer’s Common Stock outstanding as of the Closing, as reported to the Reporting Persons by the Issuer.


    CUSIP No. 878972108       13D

     

    Item 1. Security and Issuer.

    This joint statement on Schedule 13D (this “Statement”) is filed with respect to the common stock, par value $0.0001 per share (“Common Stock”), of Tectonic Therapeutic, Inc., a Delaware corporation (the “Issuer”). The address of the principal executive offices of the Issuer is 490 Arsenal Way, Suite 210, Watertown, MA 02472. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

    Item 2. Identity and Background.

    (a) This Statement is being filed by Polaris Partners IX, L.P. (“PP IX”), Polaris Partners GP IX, L.L.C. (“PP GP IX”), Polaris Founders Capital Fund I, L.P. (“PFC I”), Polaris Founders Capital Management Co. I, L.L.C. (“PFCM I”), Polaris Founders Capital Fund II, L.P. (“PFC II”) and Polaris Founders Capital Management Co. II, L.L.C. (“PFCM II”, and together with PP IX, PP GP IX, PFC I, PFCM I and PFC II, the “Reporting Entities”) and Terrance McGuire (“McGuire”), a member of the Issuer’s board of directors (the “Board”) and Jonathan Flint (“Flint”, and together with McGuire, the “Reporting Individuals”). The Reporting Entities and the Reporting Individuals are collectively referred to as the “Reporting Persons”. The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached to this Statement as Exhibit 1. Other than those securities reported herein as being held directly by such Reporting Person, each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Person’s pecuniary interest therein.

    (b) The address of the business offices of each of the Reporting Persons is One Marina Park Drive, 8th Floor, Boston, MA 02210.

    (c) PP IX, PFC I and PFC II are each a venture capital investment entity. PP GP IX, PFCM I and PFCM II are the general partners of the venture capital investment entities. McGuire is a member of the Board, a managing member of PFCM I and PFCM II and an interest holder of PP GP IX. Flint is a managing member of PFCM I and PFCM II. Each of David Barrett, Brian Chee, Amir Nashat and Amy Schulman are the managing members of PP GP IX (the “PP GP IX Managing Members”).

    (d) During the past five years, none of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

    (e) None of the Reporting Persons are, nor during the last five years have been, a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    (f) Each of PP GP IX, PFCM I and PFCM II are limited liability companies organized under the laws of the State of Delaware. Each of PP IX, PFC I and PFC II are limited partnerships organized under the laws of the State of Delaware. Each McGuire and Flint are citizens of the United States of America.

    Item 3. Source and Amount of Funds or Other Consideration.

    All of the securities reported herein as beneficially owned by the Reporting Persons were acquired in the Business Combination (as defined below). Avrobio, Inc., a Delaware corporation (“Avrobio”), and Tectonic Therapeutic, Inc., a Delaware corporation (“Tectonic”), entered into an Agreement and Plan of Merger and Reorganization (the “Business Combination Agreement”) on January 30, 2024, pursuant to which, among other matters, Alpine Merger Subsidiary, Inc., a direct, wholly owned subsidiary of Avrobio (“Merger Sub”), will merge with and into Tectonic, with Tectonic surviving as a wholly owned subsidiary of Avrobio (such transaction, the “Business Combination”). After the completion of the Business Combination, Avrobio will change its corporate name to “Tectonic Therapeutic, Inc.” with the surviving entity becoming the Issuer for purposes of this Statement.


    At the effective time of the Business Combination (the “Closing”), each share of Tectonic common stock, par value $0.0001 per share (“Tectonic Common Stock”), after giving effect to the conversion of each share of Tectonic preferred stock, par value $0.0001 per share, into Tectonic Common Stock as well as the issuance of the private financing shares (as defined below) and of Company SAFEs (as defined below) will be converted into the right to receive a number of shares of Avrobio common stock (the “Conversion Shares”), par value $0.0001 per share, equal to the exchange ratio.

    In connection with the Business Combination, certain investors, including each of PP IX and PFC II agreed to purchase shares of Tectonic Common Stock at a purchase price of $12.39908 per share subject to and immediately prior to the Closing, pursuant to the terms of a subscription agreement entered into by such investors and Tectonic, and certain investors, including PP IX and PFC II consummated certain additional purchases of Tectonic Common Stock pursuant to the conversion of certain simple agreements for future equity entered into by such investors and Tectonic (the “Company SAFEs”). The above summary is qualified by reference to such description and the full text of the Business Combination Agreement, which is filed as Exhibit 2 to this Statement and is incorporated herein by reference.

    Following the Closing, the Reporting Persons hold an aggregate of 1,157,976 shares of the Issuer’s Common Stock.

    All securities of the Issuer covered by this Statement were originally acquired by each of PP IX, PFC I, and PFC II using investment funds provided to each of PP IX, PFC I, and PFC II by their respective limited and general partner investors. Unless noted above, no part of the purchase price was borrowed by any Reporting Person for the purpose of acquiring any securities discussed in this Item 3.

    Item 4. Purpose of Transaction.

    The information set forth in Item 3 of this Statement is incorporated herein by reference. The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price and availability of shares of Common Stock or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer’s business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations and other factors considered relevant, may decide at any time to increase or to decrease the size of their investment in the Issuer in the open market, in privately negotiated transactions, pursuant to 10b5-1 trading plans or otherwise.

    McGuire is a member of the Issuer’s board of directors. In addition, McGuire, in his capacity as a director, may be entitled to receive cash compensation and equity compensation, including stock option or other equity awards, pursuant to the Issuer’s 2024 Equity Incentive Plan (the “Option Plan”), which became effective upon the Closing.

    Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

    Item 5. Interest in Securities of the Issuer.

    (a) and (b) See Items 7-11 and 13 of the cover pages of this Statement for each Reporting Person and Item 2 above.

    (c) Except as reported in this Statement, none of the Reporting Persons has effected any transactions in the Issuer’s securities within the past 60 days.

    (d) Under certain circumstances set forth in the respective limited partnership agreements of each of PP IX, PFC I, and PFC II (the “Funds”), the respective limited and general partners of the Funds may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by such entity of which they are a partner.

    (e) Not applicable.

     


    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    The information set forth in Items 3 and 4 of this Statement is incorporated herein by reference.

    The Conversion Shares held by the Funds are subject to certain lock-up restrictions, which prohibit, subject to certain limited exceptions, the sale, transfer or conveyance of any of the Conversion Shares held by the Funds for 180 days following the closing of the Business Combination. The above summary is qualified by reference to such description and the full text of the Lock-Up Agreement, which is filed as Exhibit 3 to this Statement and is incorporated herein by reference.

    McGuire, in his capacity as a director, may be entitled to receive cash compensation and equity compensation, including stock option or other equity awards, pursuant to the Option Plan, and the Issuer’s non-employee director compensation policy (the “Compensation Policy”). The terms and provisions of the Option Plan and the Compensation Policy are described in the Option Plan filed as Exhibit 10.6 to the Issuer’s Current Report on Form 8-K as filed with the Commission on June 20, 2024 (File No. 001-38537). The full text of the Option Plan is filed as Exhibit 4 to this Statement and is incorporated herein by reference.

    The Issuer has entered into indemnification agreements with its directors and executive officers. These agreements provide that the Issuer will indemnify each of its directors and executive officers to the fullest extent permitted by Delaware law. The Issuer will advance expenses, including attorneys’ fees (but excluding judgments, fines and settlement amounts), to each indemnified director or executive officer in connection with any proceeding in which indemnification is available and the Issuer will indemnify its directors and officers for any action or proceeding arising out of that person’s services as a director or officer brought on behalf of the Issuer or in furtherance of the Issuer’s rights. Additionally, certain of the Issuer’s directors may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director’s services as a director referenced herein. Nonetheless, the Issuer has agreed in the indemnification agreements that the Issuer’s obligations to those same directors are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities incurred by those directors are secondary.

    Item 7. Material to be Filed as Exhibits.

     

    Exhibit 1    Joint Filing Agreement, dated June 27, 2024, by and among the Reporting Persons (filed herewith).
    Exhibit 2    Agreement and Plan of Merger and Reorganization, dated as of January 30, 2024, by and among the Avrobio, Merger Sub and Tectonic (filed as Annex A to Avrobio’s Registration Statement on Form S-4 as filed with the Commission on April 29, 2024 (File No. 333-277048) and incorporated herein by reference).
    Exhibit 3    Form of Lock-Up Agreement for certain directors, officers and other stockholders of the Issuer (filed as Annex E to Avrobio’s Registration Statement on Form S-4 as filed with the Commission on April 29, 2024 (File No. 333-277048) and incorporated herein by reference).
    Exhibit 4    2024 Equity Incentive Plan and associated forms (filed as Exhibit 10.6 to the Issuer’s Current Report on Form 8-K as filed with the Commission on June 20, 2024 (File No. 001-38537) and incorporated herein by reference).
    Exhibit 5    Form of Indemnity Agreement by and between the Issuer and its directors and officers (filed as Exhibit 10.2 to the Issuer’s Current Report on Form 8-K as filed with the Commission on June 20, 2024 (File No. 001-38537) and incorporated herein by reference).


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: June 25, 2024

     

    POLARIS PARTNERS IX, L.P.
    By:   Polaris Partners GP IX, L.L.C.
    By:  

    /s/ Lauren Crockett

      Name: Lauren Crockett
      Title:  General Counsel
    POLARIS PARTNERS GP IX, L.L.C.
    By:  

    /s/ Lauren Crockett

      Name: Lauren Crockett
      Title:  General Counsel
    POLARIS FOUNDERS CAPITAL FUND I, L.P.
    By:   Polaris Capital Management Co. I, L.L.C.
    By:  

    /s/ Gregg Rubin

      Name: Gregg Rubin
      Title:  General Partner

    POLARIS FOUNDERS CAPITAL

    MANAGEMENT CO. I, L.L.C.

    By:  

    /s/ Gregg Rubin

      Name: Gregg Rubin
      Title:  General Partner
    POLARIS FOUNDERS CAPITAL FUND II, L.P.
    By:   Polaris Capital Management Co. II, L.L.C.
    By:  

    /s/ Harold Friedman

      Name: Harold Friedman
      Title:  Vice President

    POLARIS FOUNDERS CAPITAL

    MANAGEMENT CO. II, L.L.C.

    By:  

    /s/ Harold Friedman

      Name: Harold Friedman
      Title:  Vice President


    TERRANCE MCGUIRE
    By:  

    *

      Authorized Signatory
    JONATHAN FLINT
    By:  

    *

      Authorized Signatory
    *By:  

    /s/ Lauren Crockett

    Name:   Lauren Crockett
      Attorney-in-Fact

    [* This Statement was executed pursuant to a Power of Attorney. Note that copies of the applicable Powers of Attorney are already on file with the appropriate agencies.]

    Get the next $AVRO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AVRO

    DatePrice TargetRatingAnalyst
    12/18/2023Buy → Neutral
    Mizuho
    1/6/2022$28.00 → $6.00Buy
    Mizuho
    1/5/2022$22.00 → $6.00Overweight
    Barclays
    1/5/2022$7.00 → $3.00Equal-Weight
    Morgan Stanley
    1/5/2022Buy → Neutral
    BTIG
    1/5/2022$28.00 → $8.00Buy
    Needham
    11/19/2021$24.00 → $7.00Overweight → Equal-Weight
    Morgan Stanley
    10/12/2021$27.00 → $25.00Overweight
    Morgan Stanley
    More analyst ratings

    $AVRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Leonard Braden Michael bought $971,493 worth of shares (766,635 units at $1.27) (SEC Form 4)

      4 - AVROBIO, Inc. (0001681087) (Issuer)

      5/15/24 11:21:34 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Former 10% owner of AVROBIO Leonard Braden Michael acquired 433,688 shares (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      6/25/24 1:42:11 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Donenberg Phillip B.

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      6/24/24 4:37:33 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Vitorovic Stefan was granted 1,028,674 shares (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      6/24/24 4:35:35 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tectonic Therapeutic Appoints Daniel Lochner as Chief Financial Officer

      Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, today announced the appointment of Daniel Lochner as Chief Financial Officer of Tectonic. "Dan is an experienced public-company CFO who will add significant financial expertise to our team," said Alise Reicin, MD, President and Chief Executive Officer of Tectonic. "With his extensive background in the healthcare and biopharmaceutical industries, Dan is an important addition to the Tectonic team, and we are thrilled to welcome him as Chief Financial Officer." Dan brings with him a wealth of knowledge in corporate finance, business str

      6/3/24 4:15:00 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure

      Study to evaluate TX45 impact on cardiopulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension, a patient population in urgent need of novel therapies TX45 clinical program advancing on track based on promising initial Phase 1A data; confirmatory Phase 1A data expected mid-2024 and topline Phase 1B data expected in 2025 Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced the initiation of enrollment in the Phase 1B study for TX45, an investigational long-acting relaxin-Fc fu

      3/26/24 7:06:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tectonic Therapeutic Announces Participation at Investor Conferences in March

      Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that Alise Reicin, MD, President and Chief Executive Officer, will be participating in two investor conferences in March: TD Cowen 44th Annual Health Care Conference being held in Boston on March 4 – 6 Leerink Partners Global Biopharma Conference being held in Miami on March 11 – 13 The Tectonic management team will host one-on-one meetings during both conferences. Interested investors should contact their TD Cowen and/or Leerink rep

      2/27/24 7:00:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    SEC Filings

    See more
    • AVROBIO Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)

      6/25/24 9:52:20 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AVROBIO Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Leadership Update, Entry into a Material Definitive Agreement, Changes in Registrant's Certifying Accountant, Results of Operations and Financial Condition, Material Modification to Rights of Security Holders, Changes in Control of Registrant

      8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)

      6/20/24 4:25:03 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form 8-K/A filed by AVROBIO Inc.

      8-K/A - AVROBIO, Inc. (0001681087) (Filer)

      6/18/24 11:51:59 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • AVROBIO downgraded by Mizuho

      Mizuho downgraded AVROBIO from Buy to Neutral

      12/18/23 8:06:56 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mizuho reiterated coverage on Avrobio with a new price target

      Mizuho reiterated coverage of Avrobio with a rating of Buy and set a new price target of $6.00 from $28.00 previously

      1/6/22 6:59:42 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Barclays reiterated coverage on Avrobio with a new price target

      Barclays reiterated coverage of Avrobio with a rating of Overweight and set a new price target of $6.00 from $22.00 previously

      1/5/22 9:51:19 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    Leadership Updates

    Live Leadership Updates

    See more
    • Tectonic Therapeutic Appoints Daniel Lochner as Chief Financial Officer

      Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, today announced the appointment of Daniel Lochner as Chief Financial Officer of Tectonic. "Dan is an experienced public-company CFO who will add significant financial expertise to our team," said Alise Reicin, MD, President and Chief Executive Officer of Tectonic. "With his extensive background in the healthcare and biopharmaceutical industries, Dan is an important addition to the Tectonic team, and we are thrilled to welcome him as Chief Financial Officer." Dan brings with him a wealth of knowledge in corporate finance, business str

      6/3/24 4:15:00 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AVROBIO and Tectonic Therapeutic Announce Merger

      Combined company to be Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Tectonic's novel GPCR-targeted therapeutic proteins $130.7 million in private financing commitments with new and existing leading life sciences investors in connection with merger Combined company expected to have approximately $165 million in cash and cash equivalents at close to provide cash runway into mid-2027 Funding is expected to advance lead asset TX45, a potential best-in-class Fc-relaxin fusion protein, through multiple clinical data catalysts Tectonic's first two programs address indications with high unmet need and no approved therapies Companies to host joint webcast to

      1/30/24 8:00:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update

      On track to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment Plan to provide clinical and regulatory updates on cystinosis program in conjunction with ASGCT annual meeting in May 2023; plan to initiate late-stage cystinosis clinical trial activities in second half 2023, subject to regulatory alignment Collaborator-sponsored Phase 1/2 clinical trial for mucopolysaccharidosis type II (MPS-II), or Hunter syndrome, initiated Announced appointment of current CFO Erik Ostrowski as interim CEO AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a l

      5/11/23 7:00:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    Financials

    Live finance-specific insights

    See more
    • AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update

      Provided interim data at WORLDSymposium™ 2022 that showed sustained engraftment across first three patients 1+ year post-gene therapy in Phase 1/2 clinical triali for cystinosis; all remain off oral cysteamine to date Interim clinical data update of AVR-RD-02 in Gaucher disease type 1 planned for 2022; third patient dosed in Phase 1/2 clinical trial Regulatory interactions planned in 2022 to inform clinical development and registration strategies for programs in Gaucher disease, cystinosis, Hunter syndrome and Pompe disease Strong balance sheet with cash runway into Q1 2024 AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a li

      3/17/22 7:00:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis

      Sustained engraftment observed across first three patients 1+ year post-gene therapy; all remain off oral cysteamine to date Reduction in number of cystine crystals as measured in skin and intestinal mucosa biopsies observed across first three patients Continued favorable safety profile with no adverse events related to drug product to date Clinical proof-of-concept in adult patients lays groundwork for AVROBIO-sponsored trial planned to begin in 2023 Analyst and investor conference call scheduled for today at 8:00 a.m. ET AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today reported

      2/9/22 7:00:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022

      Analyst and investor conference call scheduled for Wednesday, Feb. 9, 2022, at 8:00 a.m. ET Five platform presentations and three posters on the company's clinical and preclinical programs for lysosomal disorders are scheduled throughout the symposium AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that updated clinical data from its ongoing, collaborator-sponsoredi Phase 1/2 clinical trial in cystinosis will be presented on Feb. 9, 2022, at the 18th Annual WORLDSymposium™ in San Diego, Calif. Additionally, preclinical data from its Pompe disease and Hunter syndrome programs, as we

      1/27/22 7:00:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by AVROBIO Inc.

      SC 13D - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      6/26/24 8:00:02 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by AVROBIO Inc.

      SC 13D - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      6/25/24 4:23:25 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by AVROBIO Inc. (Amendment)

      SC 13G/A - AVROBIO, Inc. (0001681087) (Subject)

      5/21/24 10:01:24 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care